Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.

The efficacy and safety of bimekizumab have been reported by several phase II and III clinical trials, even in a longer-term period. Moreover, clinical trials also showed bimekizumab significant higher efficacy compared to other biological classes, including anti-TNF, anti-IL-12/23, and even to another IL-17 inhibitor, secukinumab. Despite numerous biologics are currently available for psoriasis, some patients may result resistant to other treatments, and/or experience psoriatic flares during or after treatment withdrawal. In this scenario, bimekizumab may represent an additional valuable alternative for patients with moderate to severe forms of psoriasis.